Meitheal Pharma’s Lovenox Generic Earns FDA Approval

The FDA approved a generic of Sanofi’s anticoagulant Lovenox (enoxaparin) developed by Meitheal Pharmaceuticals and Nanjing King-Friend Biochemical Pharmaceuticals.

The enoxaparin sodium injection is approved as an anticoagulant for use in deep vein thrombosis abdominal surgery, hip replacement surgery, knee replacement surgery, and patients with severely restricted mobility during acute illness.

According to IQVIA data, enoxaparin had sales of approximately $616 million in the U.S. for the year ending October 2019.